{
  "docId": "019dd923-5efe-75c0-8dfe-c33214992e60",
  "docSlug": "e4e961afe28a39dc",
  "documentTitle": "2026 Investor Deck",
  "authorId": "JPMorgan-IR",
  "authorName": "Summit Therapeutics",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 7,
  "pageCount": 15,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "roadmap",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a table of clinical trials, callout boxes for collaborations and research support, and a forward-looking statement about Q1 2026.",
  "elementsJson": [
    "data_table",
    "callout_box",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/7",
  "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Summit initiating additional set of Phase III studies. Further details coming starting in Q1 2026",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "155fbe76-cf20-4e19-9e6d-6e1effcd907a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.28,
        "x": 0.02,
        "y": 0.37
      },
      "kind": "callout",
      "text": "Collaborations: RevMed (RAS(ON)i), GSK (B7-H3), More Planned in 2026",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e831bd7-4459-4742-83b8-9bdf786055ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.25,
        "x": 0.45,
        "y": 0.37
      },
      "kind": "callout",
      "text": ">60 ISTs Supported, 15 Enrolling, 5 via MD Anderson",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d5de74b-8d2d-4485-9aa6-46de576de6fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.25,
        "x": 0.73,
        "y": 0.37
      },
      "kind": "callout",
      "text": ">46 Ivonescimab Posters, Publications & Presentations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f851c1a0-96c4-4712-b108-329c71ba8c72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Present-time biopharma confidence in ivonescimab is a significant governor in our go-forward clinical development expense",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-7321-74b0-ac7d-ce5915478f1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.2,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5047d70e-69d7-4f09-8909-d12e5d7d135a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.1,
        "x": 0.32,
        "y": 0.37
      },
      "kind": "list",
      "text": "RASi and ADC focus areas",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc7b1476-7c7c-477d-846d-2accf2912e8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Clinical Trial Status",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-7321-74b0-ac7d-d100cf784277",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.96,
        "x": 0.02,
        "y": 0.09
      },
      "kind": "table",
      "text": "Clinical trial pipeline table showing Tumor Type, Study, Line & Indication, Regimen, Phase status, and current recruitment status.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68e8cdd5-10a4-4d46-b62a-a1efa355b066",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.63
      },
      "kind": "title",
      "text": "Present-time biopharma confidence in ivonescimab is a significant governor in our go-forward clinical development expense",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23c73b6e-6fa8-4350-9611-26103b4f7bdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Ivonescimab Development: Summit Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "796c44be-db9a-4a9e-b262-cdb73ff6f243",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180",
      "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential",
      "position": 0,
      "objective": "Highlighting the importance of timely progress in biopharma development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 11,
      "from": 4,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3",
      "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential",
      "position": 1,
      "objective": "Positioning Ivonescimab as a high-potential therapy",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}